# The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke

Study · id `cardio:ct-nct07167550` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07167550](<https://clinicaltrials.gov/study/NCT07167550>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07167550

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 184 participants.

## Technical summary

Registry record NCT07167550. Randomized; double masking; primary purpose treatment. Start 2025-09-06 (anticipated); primary completion 2026-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 184 participants (planned count; ClinicalTrials.gov record NCT07167550, source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)
- Planned start: 2025-09-06 (anticipated) (ClinicalTrials.gov record NCT07167550, source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)
- Primary completion: 2026-01-31 (anticipated) (ClinicalTrials.gov record NCT07167550, source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)
- Completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT07167550, source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)
- Countries: Russia (ClinicalTrials.gov record NCT07167550, source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07167550-2025-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke
- Condition: Stroke
- Condition: Acute Stroke
- Condition: Ischemic Stroke
- Condition: Cerebrovascular Disorders
- Condition: Physiological Effects of Drugs
- Intervention (Drug): Dimephosphon®
- Intervention (Drug): Placebo
- Lead sponsor: Tatchempharmpreparaty, JSC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 9cd4b6127a4eeec542bb27d04c8d3288d4af3a50c3ddcfee9e7bdaf4ddcf4d80
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
